Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT05687032

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • NanFang Hospital of Southern Medical University Guangzhou, Guangdong, China
View all 16 locations
View Trial Details
Completed

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT03391466

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UCLA Santa Monica, California, United States
View all 72 locations
View Trial Details
Completed

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

NCT04008706

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Chandler, Arizona, United States
  • Research Site Long Beach, California, United States
  • Research Site Redlands, California, United States
  • Research Site Whittier, California, United States
View all 108 locations
View Trial Details
Completed

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

NCT05364424

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Chao Family Comprehensive Cancer Center UCI Orange, California, United States
  • Memorial Cancer Institute at Memorial West Pembroke Pines, Florida, United States
  • The University of Chicago Chicago, Illinois, United States
  • Tulane Medical Center New Orleans, Louisiana, United States
View Trial Details
Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions
Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 24 locations
View Trial Details

Related conditions